Emergency Medicine Foundation   Report issue

Foundation Phase 2 Phase 3 Phase 4
Founded: Irving TX United States (1972)

Organization Overview

First Clinical Trial
2007
NCT00441792
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Emergency Medicine Foundation

Active Ingredients

Drugs in Phase 4 Trials (3)

buprenorphine (1 trial)

morphine (1 trial)

naloxone (narcan) (1 trial)

Drugs in Phase 3 Trials (1)

trimethoprim (2 trials)

Drugs in Phase 2 Trials (3)

cryoprecipitate (1 trial)

fibrinogen (human) (RiaSTAP) (2 trials)

midazolam (versed) (2 trials)

Drugs in Other Trials (3)

etomidate (amidate) (1 trial)

nitrous oxide (1 trial)

oxygen (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Abscess (Phase 3)

Emergencies (Phase 4)

Fractures, Bone (Phase 4)

Hemorrhage (Phase 2)

Hip Fractures (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 10